Treatment targeted at a genetic mutation relieves psychosis symptoms
Proof-of-principle findings pave the way for precision medicine in psychiatry
Philadelphia, July 3, 2019 – Treatment of psychosis can be targeted to a specific genetic mutation in patients with psychotic disorders, according to a study in Biological Psychiatry, published by Elsevier. The study provides a proof-of-principle demonstration that treatments can be tailored to a specific genotype, rather than diagnosis, to relieve symptoms. The findings also link an individual structural mutation to the underlying biology of psychosis and treatment response.
Genetic mutations that have large effects on psychiatric disease risk are rare, with some known to occur in only one or a few families, like the mutation described in the study led by Deborah L. Levy, PhD, McLean Hospital, a psychiatric affiliate of Harvard Medical School, Cambridge, MA, USA. The mutation was a copy number variant (CNV) in which the two patients in the study had four, instead of the usual two, copies of the GLDC gene. The authors hypothesized that this mutation might reduce brain glycine, a key factor for proper glutamatergic functioning, which is disrupted in schizophrenia.
“The compelling aspect is that this CNV can be linked to pathophysiology, and, as the new study shows, to treatment,” said Dr. Levy.
The researchers assessed whether this CNV could help guide treatment decisions by targeting the mutation to normalize its effects, a “genotype first” approach. “This approach contrasts with the standard clinical practice of treating individuals on the basis of clinical symptoms or diagnosis independent of specific genetic variants,” said Dr. Levy.
Addition of agents to restore glutamate function, glycine or D-cycloserine, to the patients’ standard medications improved psychotic symptoms in both patients beyond their usual treatment regimens. Each of the patients also saw some reductions in other symptoms, including mood symptoms and negative symptoms of schizophrenia, including enhanced emotional engagement and less social withdrawal.
“It is important to note that the two subjects studied here bore little clinical resemblance, with distinctly different symptom burdens, and highly dissimilar courses of illness,” noted first author J. Alexander Bodkin, MD, McLean Hospital. This suggests that response to the treatment arose from targeting a specific biological process, rather than clinical diagnosis per se.
“Most studies of rare structural variants will have very small sample sizes, complicating the usual approach to statistical analysis. Nevertheless, because the effects of a targeted treatment can be large, it is important to prioritize opportunities to study even small groups of patients who may benefit,” observed author Charity J. Morgan, University of Alabama, Birmingham, AL, USA.
“Psychiatry is in the very early days of precision medicine, i.e., the effort to match particular patients to the specific treatments that they need. In their article, Dr. Levy and her colleagues provide a wonderful example of this approach,” said John Krystal, MD, Editor of Biological Psychiatry. “The substances that they administered, glycine and D-cycloserine, do not produce noticeable behavioral effects in healthy people or in patients with psychotic disorders. However, because these substances replaced a deficient co-factor involved in neural communication in these particular individuals, their administration alleviated mood and psychosis symptoms. As in these cases, we expect psychiatry to develop more instances where specific treatments can be developed to meet the needs of particular groups of patients.”
Notes for editors
The article is “Targeted Treatment of Individuals with Psychosis Carrying a Copy Number Variant Containing a Genomic Triplication of the Glycine Decarboxylase Gene,” by J. Alexander Bodkin, Michael J. Coleman, Laura J. Godfrey, Claudia M. B. Carvalho, Charity Johanna Morgan, Raymond F. Suckow, Thea Anderson, Dost Ongur, Marc J. Kaufman, Kathryn E. Lewandowski, Arthur J. Siegel, Elliot Waldstreicher, Christopher M. Grochowski, Daniel C. Javitt, Dan Rujescu, Scott Hebbring, Richard Weinshilboum, Stephanie Burgos Rodriguez, Colette Kirchhoff, Timothy Visscher, Alexander Vuckovic, Allison Fialkowski, Shane McCarthy, Dheeraj Malhotra, Jonathan Sebat, Donald C. Goff, James I. Hudson, James R. Lupski, Joseph T. Coyle, Uwe Rudolph, and Deborah L. Levy (https:/
It appears in Biological Psychiatry, published by Elsevier.
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at [email protected]”>[email protected] or +1 214 648 0880. Journalists wishing to interview the authors may contact Laura Neves, McLean Hospital Media Relations, at [email protected]”>[email protected] or +1 617 855 2177.
The authors’ affiliations and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, MD, is Chairman of the Department of Psychiatry at the Yale University School of Medicine, Chief of Psychiatry at Yale-New Haven Hospital, and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available http://www.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 6th out of 142 Psychiatry titles and 9th out of 261 Neurosciences titles in the Journal Citations Reports® published by Clarivate Analytics. The 2017 Impact Factor score for Biological Psychiatry is 11.982. http://www.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. http://www.
Related Journal Article